Health Professional Radio - Podcast

Dr. Randy Schatzman, CEO at Bolt Biotherapeutics, Inc., discusses how Bolt is developing drugs to turn cold tumors "hot" to achieve an anti-tumoral activity in unresponsive patients. They are ahead of their competitors as they have already started the Phase 1 study of BDC-1001 monotherapy for patients with HER2-expressed solid tumors. He discusses how they are using the Boltbody™ Immune-Stimulating Antibody Conjugates (ISAC) approach to combat cancer and how this technology is shaping the treatment of cancers.